Android app on Google Play

Antares (ATRS) Makes New 52-Week High; Is Pfizer (PFE) Taking a Gander

July 16, 2012 2:27 PM EDT Send to a Friend
Get Alerts ATRS Hot Sheet
Price: $3.07 --0%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade ATRS Now!
Join SI Premium – FREE
Shares of Antares (Nasdaq: ATRS) have traded to a new 52-week high this afternoon. The stock is currently at $5.20, up $0.29 (5.91%) and has moved consistently higher from about the $1.50 level in Dec. 2011.

Some attribute the move to short covering (12.1% of the float is being shorted as of June 29). Others think the company might show a profit sooner than the FY13 projection (by Wall Street analysts). A third possibility is the recent action in the sector, including recent talks that Obagi Medical (Nasdaq: OMPI) will see offers from several suitors.

There was also a resurfaced rumors of Pfizer (NYSE: PFE) looking to make a bid for Antares. However, PFE may be waiting until the company files for FDA approval of its VIBEX MTX or another product that the two companies may be working on together.

ATRS focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company’s subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors.




You May Also Be Interested In


Related Categories

Analyst Comments, Rumors, Trader Talk

Add Your Comment